Blossom covers the latest that goes on with psychedelic research. We make the waterfall of new papers easier to digest, for both laypeople, psychedelic entrepreneurs, and researchers alike. We provide handy overview posts every month and research highlights every second week.
Need an overview of where the research stands at this moment? Dive in with our Research Overview.
While many of us had the chance to enjoy a vacation this summer, psychedelic researchers continued their hard work. They continued to unearth more about the therapeutic potential of these compounds. A big real-world study on at-home ketamine therapy finds promising results. At the same time, psilocybin was tested for alcoholism in a double-blind, placebo-controlled study design for the first time.
Summer is officially here and psychedelic researchers are continuing their efforts to turn these medicines into viable therapy options. Despite relatively few clinical trials being published over the month of June, we're continuing to learn more about the effects of psychedelics through the reanalysis of existing datasets and surveys.
We had the chance to speak with Dr Grace Blest-Hopley at Plant Medicine Week to discuss the work she and her colleagues are doing at Heroic Hearts, how psychedelics are helping veterans with traumatic brain injury, and more.
Category: Interviews, Research
Blossom‘s articles cover everything from the latest paper (also featured individually in our Papers Database) to analyses of research fields. From MDMA-AT for PTSD to psilocybin for TRD. We will pick apart the industry terms, e.g. MDMA-AT = MDMA-assisted therapy
Become a psychedelic insider!
With a free Blossom membership you will always be in the know.
📰 Weekly newsletter about the psychedelic research
✔️ Unlimited access to our database and original articles